Ct04065399 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ct04065399 . Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ct04065399 Today - Breaking & Trending Today

Revumenib Demonstrates Activity in Pediatric Patients With KMT2A+ Acute Leukemia

Published: April 4, 2024

Phase 2 data from the AUGMENT-101 study show that revumenib elicits responses with acceptable safety in pediatric patients with KMT2A+ acute leukemia.

Source: onclive.com

Related Topics:

Zuid HollandUnited StatesC Michel ZwaanSyndax PharmaceuticalsAmerican Society Of Pediatric Hematology OncologyPhase 2 Augment 101 Study2024 American Society Of Pediatric Hematology OncologyCt04065399 Kmt2a Rearranged Acute LeukemiaRevumenib Syndx 5613